CC (%) | CT (%) | TT (%) | C (%) | p Value* | OR (95% CI) | ||
---|---|---|---|---|---|---|---|
SSc, n=1929 | 22.2 | 49.4 | 28.4 | 46.7 | C | 0.19 | 1.06 (0.97 to 1.17) |
CC | 0.21 | 1.13 (0.93 to 1.37) | |||||
CT | 0.56 | 1.05 (0.88 to 1.25) | |||||
TT | 1 (ref) | ||||||
SSc Topo-positive, n=536 | 24.8 | 51.1 | 24.1 | 50.4 | C | 0.0042 | 1.23 (1.07 to 1.41) |
CC | 0.0049 | 1.50 (1.13 to 1.99) | |||||
CT | 0.32 | 1.14 (0.88 to 1.46) | |||||
TT | 1 (ref) | ||||||
SSc FA-positive, n=674 | 25.4 | 48.7 | 25.9 | 49.7 | C | 0.0065 | 1.19 (1.05 to 1.36) |
CC | 0.0063 | 1.43 (1.10 to 1.84) | |||||
CT | 0.09 | 1.22 (0.97 to 1.52) | |||||
TT | 1 (ref) | ||||||
Controls, n=1587 | 20.5 | 48.9 | 30.6 | 45.0 |
Additive | Recessive | Dominant | ||||
---|---|---|---|---|---|---|
p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | |
SSc Topo-positive | 0.0042 | 1.23 (1.07 to 1.41) | 0.0059 | 1.38 (1.09 to 1.73) | 0.059 | 1.25 (0.99 to 1.58) |
SSc FA-positive | 0.0064 | 1.19 (1.05 to 1.35) | 0.033 | 1.24 (1.02 to 1.53) | 0.019 | 1.29 (1.04 to 1.59) |
↵* Mantel–Haenszel meta-analysis under a fixed-effects model.
ACA, anti-centromere antibodies; dcSSc, diffuse cutaneous subtype; FA, fibrosing alveolitis; lcSSc, limited cutaneous subtype; SSc, systemic sclerosis; Topo, anti-topoisomerase I.